The Journal of Experimental Medicine
R&D Systems
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 26 September 2005 doi:10.1084/jem.20050715
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 202, Number 7, 931-939
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodriguez, P. C.
Right arrow Articles by Ochoa, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez, P. C.
Right arrow Articles by Ochoa, A. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

Paulo C. Rodriguez1, Claudia P. Hernandez1, David Quiceno1, Steven M. Dubinett3, Jovanny Zabaleta1, Juan B. Ochoa4, Jill Gilbert1, and Augusto C. Ochoa1,2

1 Tumor Immunology Program, Stanley S. Scott Cancer Center
2 Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA 70112
3 Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095
4 Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261

CORRESPONDENCE Augusto C. Ochoa: aochoa{at}lsuhsc.edu OR ochoaaugusto{at}yahoo.com

Myeloid suppressor cells (MSCs) producing high levels of arginase I block T cell function by depleting L-arginine in cancer, chronic infections, and trauma patients. In cancer, MSCs infiltrating tumors and in circulation are an important mechanism for tumor evasion and impair the therapeutic potential of cancer immunotherapies. However, the mechanisms that induce arginase I in MSCs in cancer are unknown. Using the 3LL mouse lung carcinoma, we aimed to characterize these mechanisms. Arginase I expression was independent of T cell–produced cytokines. Instead, tumor-derived soluble factors resistant to proteases induced and maintained arginase I expression in MSCs. 3LL tumor cells constitutively express cyclooxygenase (COX)-1 and COX-2 and produce high levels of PGE2. Genetic and pharmacological inhibition of COX-2, but not COX-1, blocked arginase I induction in vitro and in vivo. Signaling through the PGE2 receptor E-prostanoid 4 expressed in MSCs induced arginase I. Furthermore, blocking arginase I expression using COX-2 inhibitors elicited a lymphocyte-mediated antitumor response. These results demonstrate a new pathway of prostaglandin-induced immune dysfunction and provide a novel mechanism that can help explain the cancer prevention effects of COX-2 inhibitors. Furthermore, an addition of arginase I represents a clinical approach to enhance the therapeutic potential of cancer immunotherapies.

Abbreviations used: cAMP, cyclic adenosine monophosphate; COX, cyclooxygenase; EP, E-prostanoid; L-Arg, L-arginine; mCSF, macrophage CSF; mRNA, messenger RNA; MSC, myeloid suppressor cell; PGE2, prostaglandin E2; PGES, prostaglandin E2 synthase; SCC, squamous cell carcinoma; siRNA, small interfering RNA; VEGF, vascular endothelial growth factor.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS